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Abstract
Machine learning platforms have emerged as a new promissory technology that some argue will revolutionize work practices 
across a broad range of professions, including medical care. During the past few years, IBM has been testing its Watson for 
Oncology platform at several oncology departments around the world. Published reports, news stories, as well as our own 
empirical research show that in some cases, the levels of concordance over recommended treatment protocols between the 
platform and human oncologists have been quite low. Other studies supported by IBM claim concordance rates as high as 
96%. We use the Watson for Oncology case to examine the practice of using concordance levels between tumor boards and 
a machine learning decision-support system as a form of evidence. We address a challenge related to the epistemic authority 
between oncologists on tumor boards and the Watson Oncology platform by arguing that the use of concordance levels as 
a form of evidence of quality or trustworthiness is problematic. Although the platform provides links to the literature from 
which it draws its conclusion, it obfuscates the scoring criteria that it uses to value some studies over others. In other words, 
the platform “black boxes” the values that are coded into its scoring system.
Keywords Artificial intelligence · Decision support · Machine learning · Oncology · Watson for Oncology · IBM · Clinical 
trials
1  Introduction: decision‑support systems 
in healthcare
During the past several years, IBM has been developing, 
among others, the Watson for Oncology platform (WFO), 
which is an artificial intelligence cognitive computing 
system (see IBM 2018). Such systems are more generally 
called medical decision-support systems. These systems are 
designed to support doctors in making decisions on which 
treatment option is best suited for their patients based on 
the latest medical evidence that is available (He et al. 2019; 
Char et al. 2018). The system relies on natural language 
processing and machine learning to provide treatment 
recommendations.
Machine learning platforms are not new and have been 
operating for years within search engines, such as Google, as 
well as financial markets and many other everyday services 
(Carlson 2018; Mittelstadt 2016; Sharon 2016; Buchanan 
2015). Algorithmic decision-making is becoming increas-
ingly omnipresent in our everyday lives (Zarsky 2015). 
According to its proponents, one of the benefits of algorith-
mic decision-making is that decisions become more objec-
tive (cf. Lepri et al. 2018; D’Agostino and Durante 2018). 
Machine learning-based medical decision-support systems 
can help to identify new research findings that physicians 
may not have time to find out for themselves among the 
rapidly expanding medical literature, as well as free up time 
for patients themselves. Machine learning platforms can also 
help to speed up the identification of treatment options, help 
to reduce errors, provide cost-efficiency, help provide stand-
ardized care, as well as support oncologists through uncer-
tainty and risk. Some applications have even received FDA 
approval for diagnosis, such as the IDx-DR device, which is 
used to diagnose diabetic retinopathy (Healio 2018).
Within the medical field, machine learning platforms are 
expected to revolutionize the way in which we study and 
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diagnose disease (Hinton 2018; Thrall et al. 2018; Syeda-
Mahmood 2018). Domingos (2015, xi) has suggested that 
machine learning is different from other computational 
approaches in that machine learning platforms are able to 
“figure it out on their own, by making inferences from data.” 
The treatment options offered by the WFO platform have 
been developed between IBM and Oncologists at Memo-
rial Sloan Kettering Cancer Center in New York, which is a 
world-leading center for cancer treatment. Numerous efforts 
are underway globally to test its concordance with tumor 
board decisions (cf. Xu et al. 2019; Kim et al. 2019a, b; 
Liu et al. 2018). Concordance refers to the level to which 
the treatment options offered by the platform agree with the 
treatment options that are chosen by the oncologists at a 
certain hospital. It is also the metric IBM uses to advertise 
its platform on its website (cf. Somashekhar 2017).
Our paper is based on observations of a pilot project con-
ducted between IBM and the Department of Oncology at 
Rigshospitalet in 2017, which is Denmark’s leading hos-
pital. We use the Danish experience and compare it with 
other pilot projects IBM has conducted around the world 
and that IBM itself highlights on its own Watson for Oncol-
ogy webpage as success stories. We critically examine the 
practice of using concordance levels between tumor boards 
and the WFO decision-support system as a form of evidence, 
although we recognize the potential of the WFO platform to 
aid oncologists in their everyday work. We address a chal-
lenge related to the epistemic authority between oncologists 
on tumor boards and the Watson Oncology platform by argu-
ing that the use of concordance levels as a form of evidence 
is problematic since it does not address the fundamental 
metric of outcome of specific treatment options for differ-
ent patients. Furthermore, the WFO platform does not make 
visible the scoring criteria it uses to rank results from cancer 
clinical trials. Although WFO supports its recommendations 
with the literature that makes the treatment claims, we see 
this as masking a more fundamental problem regarding evi-
dence: how does the WFO platform score or weight different 
clinical studies with regard to quality and local applicability 
of results? We, therefore, criticize the assumption that all 
data and studies that algorithms draw on are equal in quality 
or value (cf. Jaton 2017). This tension raises the substantive 
question of how to evaluate the quality of data algorithms 
draw evidence from and how should machine learning deci-
sion-support systems be evaluated in general.
Studies suggest that cancer trials contain significant levels 
of bias. Ledford (2019), for example, argues that ethnicity 
is a major concern for geneticists with regard to studying 
cancer across populations, but is often overlooked in West-
ern clinical trials for cancer. A recent study on cancer drugs 
approved by the European Medicines Agency (EMA) argued 
that almost all studies between 2014 and 2016 were at risk 
of bias (Naci et al. 2019). Others have suggested that trials 
conducted by the pharmaceutical industry, as opposed to 
academic investigators alone, differ vastly with regard to 
their goals, whereby studies conducted by the pharmaceuti-
cal industry may not have the best interests of the patient as 
a concern, but rather focus on drug approval (Piccart et al. 
2007). Furthermore, Devasenapathy et al. (2009) suggest 
that clinical trials conducted in developing countries may 
suffer from inadequate research infrastructure, as well as 
expertise to conduct robust studies. The value judgements 
regarding which studies ought to be weighted and for what 
populations are at the heart of the problem of concordance 
as a form of evidence in the WFO platform since WFO does 
not provide scoring information regarding which studies 
are deemed more reliable and how it accounts for bias. As 
such, inexperienced oncologists may lack the training and 
understanding of how WFO operates to critically examine 
the evidence that WFO provides.
As machine learning platforms begin to proliferate, we 
suggest that several questions emerge within the medical 
field. First, how should the recommendations made by WFO 
be evaluated in relation to physician expertise of treatment 
options on a global scale? Second, what can be said about 
the multiple levels of concordance between different tumor 
boards around the world in relation to Watson Oncology? 
Third, are there better alternatives for evaluating the effec-
tiveness of machine learning platforms for cancer treatment 
other than concordance?
The pursuit of validation through global concordance 
levels is further complicated by discussions surrounding 
value-flexibility in the development of machine learning 
platforms (Hodgkin 2016). McDougall (2018), for exam-
ple, has suggested that many artificial intelligence systems 
that are developed to support medical decision-making may 
mask fixed and covert value judgements, which erode the 
important role of shared decision-making in medical treat-
ment (for a debate on this see also Di Nucci 2019; McDou-
gall 2019). McDougall suggests that in the medical field, for 
example, patient perspectives are rarely considered in devel-
oping treatment option recommendations, which suggests a 
reintroduction of medical paternalism to patient treatment 
practices. Although platforms such as Watson may provide 
exciting new opportunities to help oncologists make deci-
sions about possible treatment options at a global level, 
there is a risk that such platforms also introduce values and 
practices, which are not locally shared by physicians and 
patients alike. Following Mckinlay’s assertion that “If we 
expect computational systems to provide us with something 
as complex as explanation or evidence, it seems appropri-
ate that any epistemic assumptions we bring to bear upon 
such systems be subject to careful and rigorous analysis” 
(Mckinlay 2017, 463). The use of concordance as a form of 
evidence represents a type of “algorithmic culture” (Striphas 
2015), which we consider problematic since it lacks reliable 
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and comparable reference or metric through which patient 
outcomes can be evaluated.
2  Methods
This paper is based on 14 semi-structured qualitative inter-
views conducted by AUTHOR in 2017 and 2018 in Den-
mark. The interviews were conducted with policy-mak-
ers, hospital administrators, IBM representatives, as well 
as doctors who were involved in piloting or developing a 
broad range of machine learning platforms in their respec-
tive fields. Written informed consent was sought from the 
interviewees before the interview. The interviews were tran-
scribed and thematically analyzed for themes regarding the 
testing use and possible implementation of decision-sup-
port systems in medical care. In addition to interviews, we 
have collected and analyzed scientific publications, reports, 
media articles, as well as online documents published by 
IBM related to its oncology platform. Some of the coun-
tries where WFO has been piloted include India, China and 
South Korea. Our analysis has focused on the way in which 
the notion of concordance is used as a form of evidence to 
generate credentials through agreement between oncologists 
and the machine learn ing platform.
3  Watson for Oncology
The WFO platform seeks to address an issue that some have 
perceived to be a problem within medical treatment. Accord-
ing to Somashekhar (2017) the system “processes structured 
and unstructured data from medical literature, treatment 
guidelines, medical records, imaging, lab and pathology 
reports, and the expertise of memorial Sloan Kettering 
experts to formulate therapeutic recommendations.” The 
algorithm then suggests what treatment options the physi-
cian should use in treating the patient. The programming for 
the algorithm accounts for numerous different data sources 
that can be weighted differently. These data sources include 
different bio-markers derived from the patient (sex, age, 
type of tumor, etc.), published findings in journals, national 
treatment standards, etc. The system then comes up with a 
score regarding which treatment options are best suited for 
the patient.
This process might mask, however, bias and statistical 
errors, which are built into the system, as well as the way in 
which results have been reported from other pilot studies. 
In a recent blog post Coeira (2018), for example, provides a 
critical analysis of a study published by Somashekhar et al. 
(2018)—a study in which oncologists in an Indian hospital 
report high concordance rates with Watson for Oncology. In 
the critical review, Coeira points out numerous limitations 
of the study. These limitations included how the WFO study 
drew on a sample population which excluded many patients, 
failing to describe well enough what data were entered into 
the system and what came out of it, why concordance rates 
were calculated twice allowing for oncologists to change 
their preferred treatment options, as well as not sufficiently 
recognizing that the outcome of the study reflects a process 
and not a clinical outcome. As Coeira notes:
“So far we have got to the point where the papers’ 
results are not that WFO had a 93% concordance with 
human experts, but rather that, when humans from a 
single institution read cancer cases from that institu-
tion, and extract data specifically in the way that WFO 
needs it, and also when a certain group of breast can-
cers are excluded, then concordance is 93%. That is 
quite a list of caveats already” Coeira 2018).
In addition to the statistical criticism laid out by Coeira, 
the WFO raises a number of other concerns regarding the 
usefulness of using concordance as a form of evidence. First, 
the platform has thus far been developed on US-based treat-
ment guidelines (Kim et al. 2019a, b) and does not take into 
account differences in incidence or risk of certain kinds of 
cancers in different populations (Liu et al. 2018). Yet, dif-
ferent countries, such as Denmark, base their treatments on 
their own national guidelines that have been established by 
local expert panels. These nationally based expert panels 
also discuss, debate, and interpret the latest findings in inter-
national studies. Consequently, expert panels form value 
judgements on different studies based on their perceptions 
regarding the quality of the evidence and rigor of the meth-
ods used. Using the Sloan Kettering treatment options, the 
IBM programmers and developers are creating a de facto 
‘ground truth’ (Jaton 2017) against which other treatment 
options are measured (Kim et al. 2019a, b). This ‘ground 
truth’ is a type of bias that is introduced into the program 
(Gianfrancesco et al. 2018), since it is not compared or vali-
dated against other treatment standards. In and of itself, this 
approach may not be problematic, so long as the treatment 
standards used in the US can be proven the best treatment 
standards in the world. This variance between guidelines 
reflects value judgements that medical experts make in each 
local setting in relation to the preferred treatment options 
and evidence, which they see as trustworthy and relevant. 
IBM could address this bias using population-based studies, 
as well as long-term prospective studies, for example, or 
explaining the logic behind their scoring system. The Nordic 
countries, for example, are some of the only countries in the 
world, which maintain cancer registries for the whole popu-
lation (Tupasela et al. 2020). These data can be linked to 
personal health and treatment data, which provide a far more 
robust data set, albeit limited in terms of its applicability to 
other populations (Pukkala et al. 2018, 2009).
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Second, the global market for cancer treatments is not 
unitary. Not all medications and treatments are available or 
have been approved in a uniform manner in different mar-
kets. Therefore, there may be treatment options in the US 
that are not available in different parts of the world. This 
may also work the other way, there may be treatment options 
available elsewhere that have not been approved in the US 
yet.
Third, in reading the pilot studies that have been run in 
different countries, it becomes evident that IBM regularly 
releases new versions of its software. Liu et al. (2018), for 
example, report that they have used version 17.1 of the WFO 
software; while, Kim et al. (2019a, b) have tested version 
18.9. In trying to compare these results, it is difficult to 
ascertain how IBM has changed its program between differ-
ent versions. The WFO website does not provide information 
about version history, which essentially generates a black 
box regarding the scoring system. Many of the published 
studies do not even report the version number, making it 
even more difficult to compare different iterations of the 
WFO algorithm.
Fourth, in reading the published reports regarding WFO, 
one must note how different oncology teams use different 
sets of data points, which they entered into WFO. The Dan-
ish oncologists reported that they provided 17 data points, 
whereas Kim et al. (2019a, b) provided 13. Although not 
specifically a major problem, we see this as another situa-
tion in which opacity is introduced into the scoring system.
The opportunities and benefits that Watson may offer lie 
in its ability to cover a great deal of literature and offer a ser-
vice for countries where there may not be enough resources 
for local oncology panels to evaluate the latest findings. Its 
weakness, however, lies in the black boxing of epistemic 
value judgements regarding which studies can be considered 
of good quality and how they are weighted in the algorithmic 
decision process.
3.1  Treatment guidelines and concordance
When visiting the Watson Oncology website (https ://www.
ibm.com/watso n/healt h/oncol ogy-and-genom ics/oncol ogy/), 
one is presented with several case studies from around the 
world where various tumor boards discuss the level of con-
cordance (agreement) that their local protocols have with 
that of the platform. According to IBM “Recent studies con-
tinue to demonstrate that Watson for Oncology ‘agrees’ with 
physicians around the world in the vast majority of cases—
so experts can focus on what they do best—deliver care” 
(IBM 2018). The presented studies have been given as con-
ference presentations of “early experiences” with working 
with the platform. None of the studies represents scientific 
articles that have been peer-reviewed, although numerous 
such studies have been published to date (Kim et al. 2019a, 
b; Liu et al. 2018; Xu et al. 2019). Hospitals which have 
piloted the platform and whose preliminary findings are pre-
sented on the website include institutions in India, Mexico, 
and Thailand. The findings that are reported in the scientific 
presentations include statements such as the following: “In 
a double-blinded study, the doctors at Manipal Hospitals 
found that Watson was concordant with the tumor board rec-
ommendations in 90% of breast cancer cases” (Somashekhar 
et al. 2016; see also Somashekhar et al. 2018).
When the platform was piloted in Copenhagen, the results 
of the treatment protocols were not as good as many had 
hoped. In comparing the suggested treatment protocols of 
the 31 virtual patients to the recommended treatment options 
in use at the hospital, only about 30% matched the current 
best practice in Denmark, about 30% were somewhat similar, 
and 30% completely different from the treatment options that 
the oncologists would themselves use to treat patients. These 
findings are similar to those reported by Kim et al. (2019a, 
b) and Liu et al. (2018). In further discussions between the 
oncologists and the IBM oncology team, two main reasons 
were highlighted to account for this low level of concord-
ance. First, the platform was coded to US-based treatment 
guidelines, which meant that it did not account for nationally 
derived guidelines or preferences for treatment options. It is 
unclear, thus far, whether the levels of concordance would 
be higher if this change was to be applied to the platform. 
Second, the algorithm was programmed in such a way as to 
emphasize cancer treatment studies, which were based in 
the US. Liu et al. (2018) highlight how such preference can 
generate problems when applying the recommendations to 
non-US populations. They note that there is a “large differ-
ence between the EGDR gene mutation phenotype of lung 
cancer in China compared with that in Western countries” 
(Liu et al. 2018, 6). According to the Danish informants, 
the use of US-based studies was problematic given that the 
Danish oncologists considered many of them to be biased. 
As one doctor noted in an interview:
We only tested it in 31 patients and well it was some 
of a disappointment for us. The advice from Watson 
was seriously flawed in 1/3 and 1/3 it was okay, but 
we did not agree completely and in 1/3 we had com-
plete agreement on the advice. Watson for oncology 
only gives advice on which treatment should you 
offer the patient. Nothing else. So we have discussed 
a lot why the reason for that and probably the local 
adaptation that is missing from Watson. It was tested 
and developed in the United States. The practices in 
United States seems to be so different. So even if look-
ing at evidence which is part of the Watson technology 
that the American doctor, the board they use to score 
the level of evidence in the literature are very biased 
towards USA studies. So studies we completely dis-
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card in Europe, they look at as important studies in 
United States (Interview with a physician 2017).
According to the Danish doctors, the US guidelines did 
not match the Danish best practice guidelines, and the US-
based studies were not considered as good as the ones con-
ducted in Denmark. The Danish doctors argued that the lack 
of quality in the US studies was due to their lack of system-
atic nation-wide cancer registries and healthcare records; 
whereas, the Danish and other Nordic country studies were 
considered far more robust and representative in relation to 
validity (Pukkala et al. 2018, 2009). As such, the Danish 
oncologists placed a great deal more value on studies and 
clinical trials conducted in Denmark, or the Nordic coun-
tries, where they believed the results were more valid for the 
local national populations than those conducted in the US 
(cf. Timmermans and Berg 2003).
Other hospitals, besides those in Denmark, have also had 
less success in finding high concordance rates with Watson. 
In South Korea, for example, several pilot studies at differ-
ent hospitals found relatively low concordance rates (~ 40%) 
between the oncologists and Watson for different types of 
cancer (Choi et al. 2019; Lee et al. 2018; Ross and Swetlitz 
2017). The outcome of the pilot studies resulted in little 
interest by those hospitals to adopt the platform into their 
everyday care practices (Choi 2018).
It is interesting to note, however, that in the interviews 
which were conducted in Denmark, doctors did mention that 
such a platform may be useful for oncology departments 
or oncologists who did not have the level of expertise and 
facilities which were available in countries such as Den-
mark. As Coeira (2018), however, points out “The evidence 
in this study doesn’t yet support such a conclusion. We have 
some data on concordance, but no data on how concord-
ance affects human decisions, and no data on how changed 
decisions affects patient outcomes.” This conclusion is also 
supported by a number of studies, which have tested the 
WFO platform (Kim et al. 2019a, b; Liu et al. 2018). Inter-
estingly, however, Liu et al. (2018) note that the WFO plat-
form has been introduced to more than 70 medical institu-
tions throughout China despite the challenges that have been 
identified thus far regarding its reliability. As such, Watson 
may provide, in the future, benefits to countries where expert 
panels are not available to develop and evaluate national 
standards for care; however, without further evidence it is 
impossible to say whether the resource would be of benefit 
to the patients. It is another question, however, if such coun-
tries would also have access to the types of treatment options 
that Watson offers in the first place as well. This possibility, 
however, remains a lesser issue in relation to the question of 
concordance as a type of evidence for a medical platform. 
In the following section, we will discuss this problem in 
more detail.
3.2  Discussion: concordance as a form of evidence 
in medical decision‑making
As a form of evidence that IBM uses to market its product, 
concordance is challenging from a medical decision-making 
perspective. We see concordance as a form of evidence prob-
lematic for a number of reasons. Let us consider these prob-
lems through the following hypothetical scenarios regarding 
concordance and non-concordance.
First, if Watson is piloted with a group of oncologists and 
there is a high level of concordance between the two, what 
does this high level of concordance suggest? In the best-case 
scenario, both the Watson platform and the oncologists have 
chosen treatment options, which give the best survival rate 
outcomes possible given the state of knowledge at a given 
time. Watson’s role in this decision-making process then is 
more to confirm what the oncologists already knew and as 
such does not provide any new information that can be used 
to treat patients.
In a second scenario, there is still a high level of concord-
ance between the platform and oncologists. In this scenario, 
however, both the platform and the oncologists choose treat-
ment options that result in poor survival outcomes, or at 
least outcomes that are worse than other available treatment 
options, but neither is “aware” of this. The fact that there is 
concordance between Watson and the oncologists does not 
provide evidence that the treatment options are the best ones; 
only that the two forms of expertise agree. In this scenario, 
the oncologists are given a false sense of security because of 
the high concordance level between the two. Furthermore, 
the developers of the platform are led to believe that because 
there is concordance with the oncologists, the platform must 
be getting it “right”, thereby exacerbating the mistake.
In a third scenario, Watson provides the best possible 
treatment options, but there is a low level of concordance 
with the oncologists. In this scenario, the oncologists 
chooses sub-optimal treatment options while the platform 
does what it is hoped to do: suggest the best possible treat-
ment options available. In this scenario, the oncologists can 
choose one of two options; either discard their own expertise 
or discard the expertise of Watson. By following the options 
suggested by Watson, they end up saving more lives. By dis-
carding Watson’s suggestions, they end up harming patients 
with sub-optimal treatment options. One could argue that 
Watson was developed with this scenario in mind, being able 
to provide new options that the oncologists did not know 
about, but which end up saving more lives than the treatment 
options that the doctors are currently using. For the develop-
ers of Watson, however, it is unclear what non-concordance 
implies; is there some evidence that it is not aware of, are 
the calculations wrong, or are there different values at stake 
in calculating treatment preferences? And for the doctors 
there is the crucial epistemological question of whether they 
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have access to the relevant information, data and literature 
to be able to evaluate Watson’s suggestion and learn from it.
In a fourth scenario, Watson provides poor treatment 
options, while the options used by the doctors are optimal to 
saving lives. Here again, the doctors need to choose between 
following their own expertise or the options that the plat-
form provides. By following their own expertise, patients are 
saved, by choosing what Watson suggests they end up harm-
ing patients. This scenario is similar to that of the third one 
in that the physicians need to evaluate the validity of their 
own expertise in relation to that which the platform provides. 
Again, for the developers, there is a challenge in understand-
ing why there is a low level of concordance between the 
platform and the oncologists.
Although these scenarios are contrived and do not nec-
essarily represent real-world situations, they none-the-less 
point to an inherent problem that the use of concordance as 
a form of evidence has in the marketing of medical deci-
sion-making platforms. Concordance does not measure 
patient outcomes regarding different treatment options. As 
mentioned, non-concordance does not imply that Watson is 
wrong and may indeed lead to oncologists learning some-
thing new. As a form of evidence, however, concordance 
says little about the outcomes of chosen treatment proto-
cols, which would be of greater value for determining which 
options to choose. Nor does concordance give us any infor-
mation regarding how and why physicians would or would 
not change their treatment decisions based on Watson’s 
suggestions.
Watson’s merits lie in the fact that it can cover a great 
deal of literature in a very short time. One could argue that 
in the long run, Watson could be a useful tool in comparing 
the long-term outcomes of different treatment protocols to 
see which ones may be more effective in treating different 
types of cancers. Such an undertaking would require, how-
ever, a better understanding of how data for cancer studies 
are collected and analyzed in different context, such as, for 
example, Denmark vs the US. There are also other important 
values, which the platform should account for, such as the 
preferences of patients as to what treatment options are pref-
erable in different situations, which Watson does not account 
for (McDougall 2018).
4  Conclusion
The use of concordance levels as the only form of evidence 
in marketing is a problematic metric for validity of treatment 
options. The challenge regarding the WFO platform is that 
oncologists do not know what value judgements IBM codes 
into their algorithm regarding the scoring of different cancer 
studies. We have shown that clinical trials for cancer drugs 
contain many biases, which IBM does not make transparent 
in the platform. IBM could easily address this problem by 
making the scoring and ranking criteria more transparent. 
This would align the WFO platform with recent policy calls 
for transparency, diversity, non-discrimination as well as 
fairness in developing AI (European Union 2019). Still, it 
should be nonetheless emphasized that the opacity issue and 
the algorithmic bias issue are related but independent from 
each other, in such a way that more transparency does not 
necessarily guarantee less bias.
Although Watson is able to perform many important tasks 
relating to the collection and screening of a large amount of 
medical literature regarding cancer treatment options, it is 
still unable to evaluate the role of value judgements made 
by different oncology guidelines and clinical trials regarding 
the best treatment options. These value judgements include 
what studies are considered as valid in evaluating treatment 
options, which treatment options are made available through 
insurance and national health insurance schemes, as well 
as whether patient perspectives are included in selecting 
preferred treatment options. In revisiting our original ques-
tions, the use of concordance as a form of evidence has the 
following problems:
First, the Watson for Oncology platform is unable to 
provide criteria or explanation for the differences in expert 
judgment in different contexts. Consequently, it is diffi-
cult to evaluate why specific treatment options are ranked 
higher than others. Second, low concordance rates do 
not necessarily mean that patients in a given hospital are 
receiving poor treatment. All that can be said about it are 
that protocol choices differ between Watson and a par-
ticular set of oncologists. As we show with our scenarios, 
differences in concordance can have multiple explanations. 
Third, a better alternative would be to draw evidence from 
high-quality and validated outcomes. Such studies would 
include population studies, as well as prospective cohort 
studies. Although, Watson does this partially by consid-
ering the outcomes of studies, the platform needs to take 
more into account differences in value judgements and 
quality criteria that different oncologists and national 
boards for treatment options take into consideration. As 
we note, the quality and reliability of cancer clinical tri-
als vary greatly, with many studies containing biases 
(Copur 2019). Despite providing evidence through litera-
ture, WFO does not reveal its scoring system and how it 
accounts for possible bias in studies. Such functionality 
could be added to Watson and provide interesting new 
insight for oncologists around the world regarding differ-
ences in treatment options that oncologists choose and for 
what reason. As IBM is able to pilot and test its platform 
around the world in different contexts, it is also able to 
amass a large amount of data regarding different itera-
tions of its algorithm; that is to say different versions that 
may prioritize one form of evidence over another. Making 
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this information available would make evaluation of the 
platform easier and more transparent. Fourth, our example 
highlights how all data sets and studies are not of equal 
value. Instead, researchers, as well as oncologists, use 
numerous different quality criteria to evaluate the validity 
of oncology studies. With the WFO platform, oncologists 
do not know what the scoring criteria are regarding which 
studies are more relevant to others.
Following McDougall (2018), considerations for bias are 
not accounted for enough in developing machine learning 
platforms for medical decision-support systems (see also 
Ledford 2019; Devasenapathy et al. 2009). Many of the peo-
ple listed in the early findings’ reports have also disclosed 
funding and ownership relations to IBM. For such platforms 
to gain broader acceptance and validity, the platform needs 
to provide more transparency regarding the scoring criteria 
it uses, as well as the changes that different versions bring 
with it. Programmers and developers also need to consider 
value-flexibility in developing systems, which prioritize 
treatment options.
The platform does provide some interesting new oppor-
tunities, however. Through its piloting projects around the 
world, IBM could develop a repository of data regarding 
the different treatment guidelines and applications used in 
different countries, as well as the values that lie behind such 
treatment guidelines. As such, IBM is in a unique position 
to gather data that could hypothetically be used later to com-
pare different guidelines. To evaluate and develop evidence 
as to the best treatment guidelines, however, IBM would 
need to trace the outcomes of the patients over many years 
to see which guidelines generated the best survival and re-
occurrence outcomes among the patient populations. It is 
imperative that the suggestions made by Watson can be criti-
cally examined in light of competing treatment guidelines 
and data quality to ensure that the suggestions that it is mak-
ing are the best possible options available globally, not just 
in the US and by a small set of oncologists.
Finally, we would like to conclude by addressing a 
broader problem which the Watson for Oncology platform 
appears to point towards. Many of the machine learning plat-
forms that are developed to support medical decision-mak-
ing seem to reproduce expert knowledge, which is already 
known. This, one could argue, is not machine learning, but 
rather a form of automation (Wajcman 2017). This raises 
the question of which set of values ought to be relied on as 
guiding decision-making? This suggests that decision-sup-
port systems within medicine might always have to rely on 
locally rooted value judgements, regardless of whether IBM 
is able to offer high concordance rates between the oncolo-
gists and its platform. We suggest that further research on 
how value judgements are made in these different contexts 
will help to provide valuable insight into the quality of care 
that patients receive in different regions of the world.
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